Comparing Revenue Performance: Bristol-Myers Squibb Company or Takeda Pharmaceutical Company Limited?

Pharma Giants' Revenue Race: Bristol-Myers vs. Takeda

__timestampBristol-Myers Squibb CompanyTakeda Pharmaceutical Company Limited
Wednesday, January 1, 2014158790000001777824000000
Thursday, January 1, 2015165600000001807378000000
Friday, January 1, 2016194270000001732051000000
Sunday, January 1, 2017207760000001770531000000
Monday, January 1, 2018225610000002097224000000
Tuesday, January 1, 2019261450000003291188000000
Wednesday, January 1, 2020425180000003197812000000
Friday, January 1, 2021463850000003569006000000
Saturday, January 1, 2022461590000004027478000000
Sunday, January 1, 2023450060000004263762000000
Monday, January 1, 2024483000000004263762000000
Loading chart...

Unleashing insights

A Decade of Revenue Growth: Bristol-Myers Squibb vs. Takeda Pharmaceutical

In the ever-evolving pharmaceutical industry, revenue growth is a key indicator of a company's market position and innovation prowess. Over the past decade, Bristol-Myers Squibb Company and Takeda Pharmaceutical Company Limited have showcased contrasting revenue trajectories. From 2014 to 2023, Bristol-Myers Squibb's revenue surged by approximately 184%, reflecting its strategic acquisitions and robust product pipeline. In contrast, Takeda's revenue, already at a towering level, grew by about 140%, underscoring its dominance in the global market.

Notably, Takeda's revenue in 2023 was nearly 100 times that of Bristol-Myers Squibb, highlighting its expansive reach and diversified portfolio. However, the data for 2024 is incomplete, leaving room for speculation on future trends. As these pharmaceutical giants continue to innovate, their revenue performance will remain a focal point for investors and industry analysts alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025